Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
Emergent reduced its 2028 unsecured debt by $75 million at a discount while preserving liquidity and signaling active balance sheet management.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Emergent BioSolutions (EBS) has completed the repurchase of $75 million aggregate principal of its 3.875% Senior Unsecured Notes due 2028, as authorized by its board.
The company spent approximately $68 million of cash, implying an average repurchase price of 90.6% of face value, and reduced the outstanding principal on these notes to about $364.7 million. Emergent states that the bond buyback aligns with its goal of strengthening its financial profile and managing its balance sheet during a multi‑year transformation. The company reports a strong cash position and access to an additional $50 million under its asset‑based revolving credit facility, and plans to monitor market conditions to evaluate timing for potential refinancing of the remaining notes. Management will discuss this milestone and its broader transformation progress at upcoming Wells Fargo and H.C. Wainwright healthcare investor conferences in September 2026.
Positive
- $75 million principal reduction of 3.875% Senior Unsecured Notes due 2028
- Repurchase completed at 90.6% of face value, implying a discount capture
- Cash outlay of approximately $68 million, less than principal retired
- Outstanding Senior Unsecured Notes lowered to about $364.7 million
- Additional liquidity from $50 million available under asset‑based revolver
Negative
- None.
Details
Market move: EBS -3.25% in the Sep 3 session. 2028 notes repurchase
On Sep 3, the day this news came out, EBS closed 3.25% below the previous close. Argus tracked a trough of -3.7% from its starting point during tracking. Our momentum scanner recorded 30 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 3 session.
Key Figures
- Notes repurchased
- $75 million
- 3.875% Senior Unsecured Notes due 2028
- Cash deployed
- $68 million
- Total cash used for repurchases
- Average repurchase price
- 90.6% of face value
- Average price paid for repurchased notes
- Remaining note balance
- $364.7 million
- Outstanding balance after repurchases
- Revolving facility availability
- $50 million
- Additional availability under asset-based revolving loan facility
- Note maturity
- August 2028
- Remaining Senior Unsecured Notes
Historical Context
-
CYFENDUS contract modification valued at approximately $24 million
-
Canada standing offer secured for NARCAN nasal spray through September 2029
-
Company extended opioid overdose education efforts across U.S. colleges and Canada
-
Net loss, impairment charge, and reduced full-year 2026 guidance
-
Company discussed cross-sector preparedness collaboration against biological threats
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
senior unsecured notes financial
aggregate principal amount financial
asset-based revolving loan facility financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Repurchase reduces unsecured note balance to approximately
$364.7 million - Management to discuss this key milestone and broader transformation progress at upcoming investor conferences
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of
“This bond repurchase reflects our continued discipline in deploying capital to strengthen Emergent’s financial profile while maintaining flexibility to support our strategic growth priorities,” said Joe Papa, president and CEO of Emergent. “The transactions were executed at attractive market levels, reduced our outstanding unsecured debt and further demonstrate our commitment to prudent balance sheet management as we continue advancing our multi-year transformation plan.”
Emergent continues to maintain a strong cash position on its balance sheet and has access to an additional
Emergent management will discuss this important milestone, along with the company’s broader transformation progress, at the following investor conferences:
- 21st Annual Wells Fargo Healthcare Conference, September 9, 2026
- H.C. Wainwright 28th Annual Global Investment Conference, September 14, 2026
- Presentation and webcast to be held at 3:30 pm ET; register here. A replay will be made available on Emergent’s Investor page.
- Presentation and webcast to be held at 3:30 pm ET; register here. A replay will be made available on Emergent’s Investor page.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding our ability to opportunistically deploy capital, the potential refinancing of additional Senior Unsecured Notes and our multi-year transformation plan, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements.
These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement, as contained herein. Any such forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company's actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risks identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.